Innovation in Biotechnology InMed Pharmaceuticals is actively developing a pipeline of proprietary small molecule drug candidates targeting CB1/CB2 receptors, with applications in Alzheimer’s, ocular, and dermatological conditions, presenting opportunities for collaborations in advanced drug discovery and clinical development.

Strategic Industry Positioning As a leader in rare cannabinoid-based products through its subsidiary BayMedica, InMed provides avenues to explore partnerships in cannabinoid manufacturing, product commercialization, and supply chain integration within the expanding cannabinoid market.

Financial Growth Potential With recent funding of nearly CAD 10 million and a revenue range of 1 to 10 million dollars, InMed is poised for growth, offering potential opportunities for investment, strategic alliances, or supply agreements as the company scales its innovative drug pipeline.

Market Engagement Activities Participation in high-profile events such as the Alzheimer's Association International Conference indicates active market engagement and interest in advancing cannabinoid therapies, creating opportunities for joint research initiatives, conferences, and educational collaborations.

Leadership & Talent Development The appointment of experienced board members and scientific advisors, including Alzheimer’s experts, positions InMed for accelerated research excellence and potential partnership in groundbreaking neurodegenerative and ophthalmologic therapeutics.